CRISPR in 2026: The Honest Guide to What Gene Editing Has Actually Achieved
CRISPR has been transformative. Here is the honest guide to what it has actually accomplished.
CRISPR-Cas9 gene editing — a technology that allows precise modification of DNA sequences in living cells — has been one of the most significant biotechnology developments of the past decade, earning its discoverers the 2020 Nobel Prize in Chemistry and generating both genuine therapeutic breakthroughs and significant ethical debate. Here is the honest guide to what CRISPR has actually achieved and where it stands in 2026.
What Has Actually Been Achieved
The most significant CRISPR therapeutic achievement to date: sickle cell disease and beta-thalassemia treatment. The FDA approved Casgevy (exa-cel, a CRISPR-based therapy) in December 2023, representing the first approved CRISPR therapy. The therapy works by editing patients' own stem cells to reactivate fetal hemoglobin production, compensating for the defective hemoglobin that causes sickle cell disease. Clinical trial data showed functional cure — no pain crises — in the majority of patients followed for significant periods. This represents a genuine, documented medical breakthrough in a previously difficult-to-treat condition affecting millions of people globally.
The Pipeline and What Is Being Worked On
Beyond sickle cell, the CRISPR therapeutic pipeline in 2026 includes: cancer treatments using CRISPR-edited T cells engineered to target specific tumor antigens; potential treatments for inherited blindness conditions; approaches to HIV by targeting viral DNA integrated into patient cells; and cardiovascular risk reduction by editing genes affecting cholesterol metabolism. These are at varying stages of clinical trial, with some showing promising early data and others earlier in development. The translation from promising animal models to successful human therapies remains the most consistent challenge — many approaches that work in mice do not translate to human results.
The Ethical Issues That Remain Unresolved
The He Jiankui case — the Chinese researcher who created the first gene-edited human babies in 2018, editing embryos for CCR5 resistance to HIV and implanting them — remains the most dramatic example of CRISPR ethics violation and prompted significant international discussion about governance of germline (heritable) gene editing. The scientific and ethics communities broadly agree that germline editing for clinical purposes is premature; somatic (non-heritable) gene therapy in consenting adults is the current acceptable framework. The longer-term questions about enhancement versus treatment, access equity for expensive therapies, and governance of heritable genome modification remain actively debated without resolution.
Bottom Line: First approved CRISPR therapy: Casgevy for sickle cell disease and beta-thalassemia (FDA approval December 2023) — editing patients' own stem cells to reactivate fetal hemoglobin, with clinical data showing functional cure in majority of patients. Active pipeline: cancer T-cell therapies, inherited blindness, HIV targeting, cardiovascular risk reduction — at varying trial stages. Ethical consensus: germline (heritable) editing for clinical use is premature; somatic gene therapy in consenting adults is the accepted current framework. He Jiankui case remains the defining ethics violation and prompted international governance discussion without resolution on enhancement, access equity, and heritable modification.